Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8633 |
High Similarity |
NPD3027 |
Phase 3 |
0.8497 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8431 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8387 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.828 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.825 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.825 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.825 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8194 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8194 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8194 |
Intermediate Similarity |
NPD37 |
Approved |
0.8141 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8099 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8089 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8042 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8039 |
Intermediate Similarity |
NPD1512 |
Approved |
0.8038 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8038 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8038 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8038 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8012 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7987 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7975 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7974 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7949 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7927 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7911 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7908 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7892 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7879 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7853 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7844 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7831 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7823 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7818 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7817 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7798 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7798 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7784 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7771 |
Intermediate Similarity |
NPD7054 |
Approved |
0.777 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7736 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7725 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7688 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7687 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7687 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7687 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7677 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7665 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7662 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7622 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7622 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7622 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7616 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.761 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7607 |
Intermediate Similarity |
NPD919 |
Approved |
0.7603 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7584 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7576 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7566 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7558 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7551 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7533 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7531 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7531 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7529 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7517 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7483 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7469 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7468 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7467 |
Intermediate Similarity |
NPD943 |
Approved |
0.7465 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7448 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7448 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7439 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7427 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7425 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7421 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD5403 |
Approved |
0.741 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7405 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7405 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7405 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7396 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD228 |
Approved |
0.7379 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7375 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7372 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7355 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7346 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7342 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD2796 |
Approved |
0.733 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7324 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7299 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7296 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7279 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7262 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7261 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7261 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7261 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7239 |
Intermediate Similarity |
NPD5089 |
Approved |
0.7239 |
Intermediate Similarity |
NPD5090 |
Approved |
0.7233 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7226 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7219 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7211 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7197 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7197 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7179 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7176 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7134 |
Intermediate Similarity |
NPD4534 |
Discontinued |
0.7125 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7124 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7122 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7122 |
Intermediate Similarity |
NPD3022 |
Approved |
0.712 |
Intermediate Similarity |
NPD2493 |
Approved |
0.712 |
Intermediate Similarity |
NPD2494 |
Approved |
0.7107 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7104 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7075 |
Intermediate Similarity |
NPD1281 |
Approved |
0.707 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.707 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.707 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.707 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.707 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.707 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7044 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7041 |
Intermediate Similarity |
NPD6746 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD3452 |
Approved |
0.7027 |
Intermediate Similarity |
NPD3450 |
Approved |
0.7027 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7025 |
Intermediate Similarity |
NPD5958 |
Discontinued |
0.7024 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7012 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7005 |
Intermediate Similarity |
NPD4583 |
Approved |
0.7005 |
Intermediate Similarity |
NPD4582 |
Approved |
0.7 |
Intermediate Similarity |
NPD2488 |
Approved |
0.7 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD2490 |
Approved |
0.7 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.6993 |
Remote Similarity |
NPD3268 |
Approved |
0.6968 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6968 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6968 |
Remote Similarity |
NPD447 |
Suspended |
0.6962 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6952 |
Remote Similarity |
NPD7680 |
Approved |
0.6952 |
Remote Similarity |
NPD4004 |
Approved |
0.6952 |
Remote Similarity |
NPD4002 |
Approved |
0.6949 |
Remote Similarity |
NPD3534 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD4585 |
Approved |
0.6943 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6943 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6941 |
Remote Similarity |
NPD4666 |
Phase 3 |
0.6939 |
Remote Similarity |
NPD4626 |
Approved |
0.6933 |
Remote Similarity |
NPD8651 |
Approved |
0.6932 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6913 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6909
|
Remote Similarity |
NPD7458 |
Discontinued |